Literature DB >> 22526172

[Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")].

M M Heck1, J E Gschwend, M Retz.   

Abstract

This article summarizes contemporary standards in systemic therapy for urothelial carcinoma as well as updated results of peer-reviewed publications and international bladder cancer meetings in 2011. Both neoadjuvant and adjuvant trials for locally advanced carcinoma and data on systemic chemotherapy for metastatic bladder cancer are discussed.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22526172     DOI： 10.1007/s00120-012-2822-9

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  19 in total

1.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era.

Authors:  Richard E Hautmann; Jürgen E Gschwend; Robert C de Petriconi; Martina Kron; Bjoern G Volkmer
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

2.  Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.

Authors:  James M G Larkin; Rosalie A Fisher; Lisa M Pickering; S Aslam Sohaib; Marwan Ghosn; Tim Christmas; Ruth L M Cordiner; Martin E Gore
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

3.  Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-21       Impact factor: 20.096

4.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

Authors:  Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 5.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

6.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Authors:  Jun Guo; Lu Si; Yan Kong; Keith T Flaherty; Xiaowei Xu; Yanyan Zhu; Christopher L Corless; Li Li; Haifu Li; Xinan Sheng; Chuanliang Cui; Zhihong Chi; Siming Li; Mei Han; Lili Mao; Xuede Lin; Nan Du; Xiaoshi Zhang; Junling Li; Baocheng Wang; Shukui Qin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

7.  Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).

Authors:  Emil Scosyrev; Benjamin W Ely; Edward M Messing; V O Speights; H Barton Grossman; David P Wood; Ralph W de Vere White; Nicholas J Vogelzang; Donald L Trump; Ronald B Natale; Catherine M Tangen; E David Crawford; Ian M Thompson
Journal:  BJU Int       Date:  2010-11-24       Impact factor: 5.588

8.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

9.  Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.

Authors:  Karel A Hinnen; Michael Schaapveld; Marco van Vulpen; Jan J Battermann; Henk van der Poel; Inge M van Oort; Joep G H van Roermund; Evelyn M Monninkhof
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

Review 10.  Adjuvant chemotherapy for invasive bladder cancer (individual patient data).

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.